收藏切换
Analysis of safety risks and regulatory responses during drug clinical trials
收藏切换
PDF
Wen-ya TANG, Min LIU, Feng XUE, Hai-xue WANG
Chinese Journal of Clinical Pharmacology | 2026, 42(3) : 439 - 444
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(3): 439-444
Drug Evaluation and Administration
Analysis of safety risks and regulatory responses during drug clinical trials
Full
Wen-ya TANG, Min LIU, Feng XUE, Hai-xue WANG
Affiliations
  • Center for Drug Evaluation National Medical Products Administration, Beijing 100163, China
Published: 2026-02-17 doi: 10.13699/j.cnki.1001-6821.2026.03.022
Outline
收藏切换
Objective

To provide practical references for all participants in drug clinical trials on drug safety risk management and promote the construction of a more efficient clinical trial safety management system.

Methods

Based on the regulatory practice of 40 clinical trial safety risk control cases from the Center for Drug Evaluation in 2024, this paper uses classified statistics and correlation analysis methods to analyze the characteristics of safety risk information from multiple dimensions such as drug types and indications, and systematically sorts out the response logic of regulatory measures.

Results

Among the 40 cases where risk management procedures were initiated, distinct risk characteristics were observed across different drug types and indications. The regulatory measures reflected the principle of matching the intensity of control with the risk characteristics.

Conclusion

Regulatory authorities have adopted differentiated regulatory requirements in accordance with the logic of risk classification and bottom-line thinking. The regulatory initiatives have gradually evolved into focusing on the optimization and full-chain improvement of sponsors’ risk management systems, providing crucial support for the protection of subjects’ rights and interests as well as the high-quality development of pharmaceutical innovation..

drug clinical trial  /  safety risk  /  pharmacovigilance  /  risk control measures  /  regulatory requirements
Wen-ya TANG, Min LIU, Feng XUE, Hai-xue WANG. Analysis of safety risks and regulatory responses during drug clinical trials[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (3) : 439 -444 . DOI: 10.13699/j.cnki.1001-6821.2026.03.022
Year 2026 volume 42 Issue 3
PDF
152
33
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.03.022
  • Receive Date:2025-09-22
  • Online Date:2026-08-06
  • Published:2026-02-17
Article Data
Affiliations
History
  • Received:2025-09-22
Affiliations
    Center for Drug Evaluation National Medical Products Administration, Beijing 100163, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.03.022
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT